Fig. 4.
a Illustration of the experimental protocols. Arrow indicates time of intravenous administration of the mitochondrial KATP channel blocker 5-hydroxydecanoate (5-HD). b 5-HD abolished cardioprotection established by immediate (IPost10″) and early (IPost10′) IPost, but had no effect on cardioprotection conferred by delayed IPost (IPost30′and IPost45′). Infarct sizes are presented as percentages of the areas at risk. Individual data and mean ± SD are shown. **P < 0.01; *P < 0.05; n.s.—not significant